Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,917.55 +1,772.89 (+2.72%) CMC Crypto 200
1,365.69 -8.15 (-0.59%)
DHR Dec 2024 260.000 call
| Previous close | 21.06 |
| Open | 24.50 |
| Bid | 24.60 |
| Ask | 25.50 |
| Strike | 260.00 |
| Expiry date | 2024-12-20 |
| Day's range | 24.43 - 24.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 172 |
ZacksDanaher (DHR) Rides on Business Strength Amid Headwinds
Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
The TelegraphQuestor: This biotech giant is backed by the world’s best fund managers
Remember Abcam? The Cambridge-based biotech was a darling of the Aim market until it decided in late-2022 to abandon London in favour of a listing on the US exchange Nasdaq.
PR NewswireDanaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI. As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially establish correlations between a new biomarker panel and clinical outcomes.
